Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
Mary Anne Fenton, Paolo Tarantino, Stephanie L. Graff
Current Oncology (2023) Vol. 30, Iss. 12, pp. 10211-10223
Open Access | Times Cited: 11

Showing 11 citing articles:

Treatment advances across the cervical cancer spectrum
Alex Francoeur, Bradley J. Monk, Krishnansu S. Tewari
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 2
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 500-500
Open Access | Times Cited: 6
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Isabella Michelon, Caio Castro, Thiago Madeira, et al.
Cancer Treatment Reviews (2025) Vol. 133, pp. 102882-102882
Closed Access
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
Éric Larose, Xinying Hua, Silin Yu, et al.
Cancer Drug Resistance (2025)
Open Access
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies
Tala Najdi, Lucile Awad, Antoine Chartouni, et al.
Investigational New Drugs (2025)
Open Access
Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances
Lorenzo Guidi, Laura Boldrini, Dario Trapani, et al.
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 3
Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer
Han Luo, Yue Sun, Tiefeng Xu
Frontiers in Medicine (2025) Vol. 12
Open Access
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care
Emna El Gazzah, Scott Parker, Mariaelena Pierobon
Expert Review of Molecular Diagnostics (2025)
Closed Access
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Sabah Alaklabi, Arya Mariam Roy, Paola Zagami, et al.
JCO Oncology Practice (2024)
Closed Access | Times Cited: 1
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis
Francesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
Cancer Treatment Reviews (2024) Vol. 132, pp. 102865-102865
Open Access | Times Cited: 1
Safety Profile of Sacituzumab Govitecan in Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, et al.
The Breast (2024) Vol. 79, pp. 103853-103853
Open Access | Times Cited: 1
Clinical cell-surface targets in metastatic and primary solid cancers
Marina N. Sharifi, Yue Shi, Matthew R. Chrostek, et al.
JCI Insight (2024) Vol. 9, Iss. 18
Open Access
Page 1

Scroll to top